Advancing Kidney Transplantation in Black Patients: A Genetics-Based Approach
Author Information
Author(s): H. Ali, Wisit Cheungpasitporn, Franco H. Cabeza Rivera, Yahya Makkeyah, Malik Shafi, Ákos G. Pethő, Pradeep Vaitla, Tibor Fülöp
Primary Institution: University Hospitals of North Midlands, Stoke-on-Trent, UK
Hypothesis
Can personalized induction therapy improve kidney transplantation outcomes for Black patients?
Conclusion
Personalized induction therapy that considers genetic and immunological profiles can enhance transplant success and reduce health disparities.
Supporting Evidence
- Induction therapy is crucial for reducing delayed graft function and improving graft survival.
- NICE guidelines favor basiliximab but may not suit high-risk patients.
- KDIGO and ERBP guidelines advocate for personalized approaches in high-risk groups.
- Black patients often face higher immunological risks requiring tailored therapies.
- Genetic markers like HLA alleles and CYP3A5 variants influence transplant outcomes.
- Personalized medicine can address health disparities in kidney transplantation.
Takeaway
This study suggests that using genetic information can help doctors choose the best treatment for Black patients getting kidney transplants, making the process safer and more effective.
Methodology
The review involved a literature search of recent articles on renal transplantation and induction therapy, focusing on genetic considerations for Black patients.
Potential Biases
The underrepresentation of Black individuals in clinical trials may lead to less effective treatment protocols for this group.
Limitations
The guidelines lack a clear definition of high-risk groups, particularly for Black patients and those with donor-specific antibodies.
Participant Demographics
The review focuses on Black patients undergoing kidney transplantation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website